Tolga Tanguler Sells 1,469 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now owns 13,191 shares in the company, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Alnylam Pharmaceuticals Trading Up 0.2 %

NASDAQ ALNY opened at $253.74 on Friday. The company has a market cap of $32.73 billion, a price-to-earnings ratio of -96.85 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business’s fifty day moving average is $271.93 and its 200 day moving average is $240.19.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter last year, the firm earned $1.15 earnings per share. The company’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on ALNY. Piper Sandler reiterated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Huntington National Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the 2nd quarter worth about $26,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at about $42,000. Finally, True Wealth Design LLC grew its position in shares of Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.